foreign
medic
devic
multipl
risk
factor
often
present
patient
addit
frequent
use
antimicrobi
agent
variou
indic
prophylaxi
empir
therapi
preemptiv
administr
specifi
c
target
therapi
occasion
mainten
suppress
therapi
impact
natur
spectrum
infect
emergenceselect
multidrugresist
mdr
organ
particular
concern
bacteri
infect
tend
occur
earli
neutropen
episod
fungal
infect
uncommon
stage
neutropenia
persist
risk
fungal
infect
increas
period
chang
epidemiologyspectrum
infect
patient
leukemia
import
conduct
period
epidemiolog
susceptibilityresist
survey
especi
institut
deal
larg
number
patient
order
detect
shift
chang
susceptibilityresist
pattern
sinc
empir
therapi
larg
base
inform
survey
conduct
everi
year
institut
fever
defi
ned
infecti
diseas
societi
america
singl
oral
temperatur
temperatur
sustain
h
period
consist
sign
infect
occur
without
focal
sign
symptom
greater
episod
fever
neutropen
patient
acut
leukemia
like
caus
infect
noninfecti
caus
includ
drug
fever
fever
relat
underli
malign
transfus
reaction
allerg
reaction
chapter
focu
current
epidemiolog
infect
patient
acut
leukemia
infect
occur
patient
malign
lymphoma
occur
consequ
treatment
specifi
c
modal
eg
monoclon
antibodi
nucleosid
analog
dealt
separ
febril
episod
neutropen
patient
classifi
ed
three
distinct
categori
clinic
document
infect
presenc
clinic
radiograph
featur
infect
cellul
pneumonia
without
microbiolog
confi
rmation
microbiolog
document
infect
posit
cultur
signifi
cant
site
unexplain
fever
formerli
fever
unexplain
origin
fuo
fever
posit
cultur
clinicalradiograph
featur
infect
clinic
document
infect
account
febril
episod
neutropen
patient
fig
defi
ned
presenc
site
suggest
infect
cellul
pneumonia
esophag
enterocol
without
microbiolog
document
caus
pathogen
infect
may
due
variou
reason
includ
use
antimicrobi
prophylaxi
render
microbiolog
cultur
neg
andor
blunt
infl
ammatori
respons
result
lack
specimen
eg
sputum
cultur
vast
major
episod
respond
empir
antimicrobi
therapi
provid
indirect
evid
due
infecti
process
microbiolog
document
infect
also
account
febril
episod
neutropen
patient
fig
major
monomicrobi
ie
caus
singl
pathogen
polymicrobi
infect
document
increas
frequenc
recent
data
show
bacteremia
neutropen
patient
includ
catheterrel
infect
polymicrobi
infect
involv
deep
tissu
site
predominantli
polymicrobi
includ
neutropen
enterocol
perirect
infect
complic
skinskin
structur
infect
pneumonia
major
polymicrobi
infect
caus
multipl
bacteri
pathogen
gramposit
gramneg
occasion
anaerob
organ
although
bacteri
fungal
bacteri
viral
infect
also
coexist
common
import
site
infect
patient
acut
leukemia
list
tabl
overal
respiratori
tract
common
site
infect
approxim
patient
acut
leukemia
develop
pulmonari
infi
ltrate
episod
neutropenia
last
day
longer
part
respiratori
tract
includ
oropharynx
upper
airway
paranas
sinus
also
frequent
site
infect
pulmonari
infi
ltrate
secondari
infecti
process
bacteri
fungal
organ
predomin
although
often
quit
diffi
cult
establish
specifi
c
microbiolog
diagnosi
noninfecti
caus
pulmonari
infi
ltrate
alveolar
hemorrhag
drug
toxic
much
less
common
consequ
empir
therapi
direct
anticip
pathogen
gener
administ
patient
modifi
ed
confi
rmatori
microbiolog
data
becom
avail
manag
patient
pulmonari
infectionscompl
discuss
detail
els
approxim
patient
acut
leukemia
neutropenia
develop
bloodstream
infect
includ
primari
bacteremia
central
lineassoci
infect
gramposit
bacteria
isol
often
time
organ
colon
skin
eg
staphylococcu
speci
bacillu
speci
corynebacterium
speci
predomin
patient
oral
intestin
mucos
viridan
group
streptococci
vg
enterococci
includ
vre
enter
gramneg
organ
common
pathogen
frequenc
gramneg
bacteremia
lower
patient
receiv
antibacteri
prophylaxi
agent
fl
uoroquinolon
patient
receiv
prophylaxi
fungemia
occur
time
caus
often
candida
speci
often
associ
indwel
central
venou
cathet
except
fusarium
speci
invas
mold
infect
seldom
caus
fungemia
small
proport
bacterem
infect
caus
nontubercul
mycobacteria
urinari
tract
infect
document
patient
acut
leukemia
especi
patient
requir
placement
shortterm
longterm
urinari
drainag
cathet
gramneg
bacteri
pathogen
escherichia
coli
predomin
although
candida
speci
uncommon
patient
urinari
cathet
stent
devic
receiv
multipl
cours
broadspectrum
antibacteri
therapi
previou
episod
neutropen
fever
common
skin
skin
structur
infect
includ
cellul
infect
phlebotomi
punctur
wound
surgic
site
infect
patient
undergon
recent
surgeri
uncommon
seriou
infect
includ
pyomyos
occasion
caus
e
coli
necrot
fasciiti
condit
usual
requir
surgic
intervent
addit
antimicrobi
therapi
even
less
common
primari
cutan
mold
infect
infect
along
gastrointestin
tract
uncommon
prior
frequent
use
antifung
prophylaxi
thrush
esophag
caus
mainli
candida
speci
occasion
herp
virus
commonplac
azol
echinocandin
prophylaxi
render
infect
larg
histor
interest
neutropen
enterocol
typhliti
occur
primarili
patient
acut
leukemia
receiv
therapi
agent
eg
cytosin
arabinosid
combin
idarubicin
anoth
anthracyclin
caus
highgrad
intestin
mucos
although
describ
increas
frequenc
patient
receiv
mucotox
antineoplast
agent
taxan
vinorelbin
perirect
infect
occur
often
patient
preexist
local
lesion
fi
ssure
hemorrhoid
true
abscess
format
uncommon
patient
sever
prolong
neutropenia
surgic
drainag
almost
alway
benefi
cial
recent
epidemiolog
data
document
predomin
gramposit
pathogen
microbiolog
document
infect
unfortun
data
focu
monomicrobi
bacterem
infect
provid
detail
site
infect
polymicrobi
infect
give
incomplet
skew
view
microbiolog
infect
sinc
bacteremia
caus
often
gramposit
organ
colon
skin
wherea
infect
site
lung
intestin
tract
urinari
tract
predomin
gramneg
pathogen
addit
polymicrobi
infect
gramneg
compon
caus
multipl
gramneg
speci
site
infect
polymicrobi
infect
taken
consider
substanti
differ
pictur
emerg
gramneg
pathogen
almost
frequent
gramposit
pathogen
inde
institut
report
predomin
gramneg
pathogen
knowledg
local
epidemiolog
pattern
critic
empir
regimen
need
design
inform
mind
microorgan
isol
often
neutropen
patient
list
tabl
commonli
isol
organ
isol
overal
coagulaseneg
staphylococci
con
organ
gener
low
virul
seldom
caus
seriou
lifethreaten
infect
catheterrel
bacteremia
common
infect
caus
con
often
treat
antimicrobi
agent
without
remov
offend
cathet
although
infect
may
recur
cathet
retain
one
except
staphylococcu
lugdunensi
resembl
aureu
virul
infect
caus
speci
need
manag
like
caus
aureu
gramposit
organ
frequent
colon
human
skin
often
caus
infect
patient
leukemia
includ
bacillu
speci
corynebacterium
speci
micrococcu
speci
like
con
common
infect
caus
organ
catheterrel
bacteremia
occasion
mention
earlier
infect
caus
aureu
virul
associ
substanti
morbid
mortal
cancer
treatment
center
organ
may
methicillin
resist
although
institut
region
differ
occur
resist
rate
netherland
scandinavian
countri
isol
also
develop
toler
reduc
suscept
vancomycin
socal
mic
creep
slow
respons
overt
failur
vancomycin
therapi
report
especi
infect
caus
organ
vancomycin
mic
recent
studi
mrsa
bacteremia
cancer
patient
comprehens
cancer
center
high
treatment
failur
rate
vancomycin
demonstr
vancomycin
mic
found
independ
factor
vancomycin
failur
base
similar
report
current
recommend
consid
therapi
altern
agent
linezolid
daptomycin
infect
caus
organ
reduc
suscept
vancomycin
alphahemolyt
viridan
group
streptococci
major
compon
human
oral
microfl
ora
mani
year
consid
contamin
organ
low
virul
even
neutropen
patient
howev
subsequ
clinic
experi
shown
respons
seriou
lifethreaten
infect
patient
popul
consist
predispos
factor
infect
organ
appear
highdos
chemotherapi
agent
cytosin
arabinosid
induc
sever
mucos
damag
therebi
facilit
entri
organ
bloodstream
probabl
predispos
factor
includ
antimicrobi
prophylaxi
fl
uoroquinolon
might
encourag
select
overgrowth
organ
treatment
chemotherapyinduc
gastriti
antacid
histamin
type
antagonist
streptococcu
miti
sangui
salivariu
predomin
speci
bacteremia
common
manifest
patient
rapidli
progress
dissemin
infect
sometim
refer
streptococc
toxic
shock
syndrom
occur
involv
bloodstream
lung
central
nervou
system
skin
despit
prompt
aggress
antimicrobi
therapi
mortal
associ
syndrom
increas
concern
report
vg
nonsuscept
overtli
resist
penicillin
limit
util
penicillin
g
penicillin
prevent
treatment
infect
isol
current
suscept
vancomycin
although
toler
describ
use
antibiot
combin
may
necessari
especi
toler
organ
organ
also
suscept
newergener
quinolon
eg
moxifl
oxacin
daptomycin
linezolid
clinic
experi
agent
limit
enterococci
resid
primarili
intestin
tract
caus
varieti
infect
bacteremia
urinari
tract
infect
endocard
intraabdomin
pelvic
infect
biliari
tract
infect
occasion
pneumonia
mening
seldom
primari
pathogen
seen
often
follow
prolong
therapi
broadspectrum
cephalosporin
carbapenem
intrins
resist
increas
use
vancomycin
especi
neutropen
cancer
patient
least
part
respons
emerg
vancomycinresist
enterococci
vre
global
organ
account
enterococc
isol
fecal
colon
vre
uncommon
patient
acut
leukemia
recipi
stem
cell
transplant
approxim
patient
vre
fecal
colon
go
develop
bacteremia
signifi
cant
infect
organ
follow
chemotherapi
expert
recommend
empir
use
agent
activ
vre
patient
develop
fever
episod
neutropenia
attempt
erad
fecal
colon
vre
singularli
unsuccess
consequ
infect
control
measur
reduc
transmiss
vre
overrid
import
gastrointestin
tract
serv
import
sourc
infect
neutropen
patient
predomin
pathogen
enter
gramneg
bacilli
use
antibacteri
prophylaxi
highrisk
patient
includ
acut
leukemia
led
reduct
frequenc
document
gramneg
infect
although
center
report
revers
trend
nevertheless
gramneg
infect
occur
gener
associ
greater
morbid
mortal
infect
caus
gramposit
counterpart
multipl
surveil
studi
shown
e
coli
klebsiella
spp
p
aeruginosa
remain
three
commonli
isol
gramneg
organ
neutropen
patient
collect
caus
microbiolog
document
gramneg
infect
enterobacteriacea
enterobact
spp
citrobact
spp
serratia
spp
proteu
spp
less
common
although
institut
differ
exist
despit
overal
declin
frequenc
gramneg
infect
neutropen
patient
increas
proport
infect
caus
nonfer
gramneg
bacilli
nfgnb
acinetobact
spp
nonaeruginosa
pseudomona
spp
stenotrophomona
maltophilia
collect
nfgnb
caus
document
gramneg
infect
proport
gradual
increas
year
overal
spectrum
infect
caus
gramneg
bacilli
wide
pneumonia
primari
catheterrel
bacteremia
urinari
tract
infect
common
tabl
p
aeruginosa
frequent
isol
import
pathogen
nfgnb
set
caus
gramneg
infect
addit
common
gramneg
organ
isol
polymicrobi
infect
organ
propens
develop
resist
antimicrobi
agent
multipl
mechan
recent
studi
demonstr
risk
factor
associ
multidrugresist
p
aeruginosa
infect
use
carbapenem
monotherapi
day
histori
p
aeruginosa
infect
preced
year
histori
chronic
obstruct
pulmonari
diseas
consequ
antimicrobi
stewardship
program
institut
target
prolong
use
carbapenem
monotherapi
result
decreas
frequenc
infect
mdr
p
aeruginosa
stenotrophomona
maltophilia
colonizationinfect
rate
neutropen
patient
especi
acut
leukemia
recipi
hsc
transplant
increas
consider
past
two
three
decad
surveil
studi
conduct
univers
texa
md
anderson
cancer
center
document
increas
proport
maltophilia
gramneg
bacilli
isol
patient
prolong
neutropenia
expos
broadspectrum
antibiot
especi
carbapenem
requir
mechan
ventil
higher
risk
infect
although
infect
also
seen
patient
without
tradit
risk
factor
shift
trimethoprimsulfamethoxazol
tmpsmx
potent
activ
maltophilia
fl
uoroquinolon
much
less
activ
maltophilia
prefer
agent
antimicrobi
prophylaxi
highrisk
neutropen
patient
may
also
contribut
increas
infect
caus
organ
tmpsmx
remain
agent
choic
treatment
infect
caus
maltophilia
vitro
resist
appear
increas
ticarcillinclavulan
also
reliabl
activ
wherea
betalactam
ceftazidim
cefepim
piperacillin
tazobactam
variabl
activ
organ
newer
quinolon
moxifl
oxacin
activ
older
agent
ciprofl
oxacin
abscess
format
uncommon
patient
sever
prolong
neutropenia
levofl
oxacin
minocyclin
novel
glycylcyclin
tigecyclin
also
activ
mani
maltophilia
isol
clinic
experi
agent
tmpsmx
ticarcillinclavulan
limit
combin
regimen
base
suscept
individu
isol
often
employ
less
common
import
nfgnb
includ
acinetobact
spp
achromobact
alcaligen
spp
burkholderia
spp
chryseobacterium
spp
nonaeruginosa
pseudomona
speci
p
putida
p
fl
uorescen
clinic
import
organ
increas
recent
year
frequent
caus
outbreak
mdr
infect
mani
outbreak
trace
sourc
contamin
dialysi
fl
uid
chlorhexidin
solut
deioniz
water
mechan
ventil
wherea
bacteri
infect
predomin
fi
rst
day
sever
neutropenia
invas
fungal
infect
start
develop
neutropenia
persist
prior
avail
agent
like
fl
uconazol
invas
candidiasi
without
hematogen
dissemin
common
candida
albican
predomin
speci
isol
frequenc
invas
candidiasi
substanti
reduc
routin
usag
antifung
prophylaxi
azol
echinocandin
highrisk
patient
manifest
like
candida
esophag
chronic
dissemin
hepatosplen
candidiasi
becom
increasingli
histor
interest
use
agent
also
led
emerg
candida
spp
candida
albican
frequent
pathogen
set
although
c
albican
continu
singl
common
speci
isol
region
differ
document
preponder
differ
candida
speci
differ
center
differ
may
repres
diverg
use
antifung
prophylaxi
andor
geograph
divers
consequ
local
epidemiolog
suscept
data
use
guid
empir
target
therapi
yeast
encount
set
includ
trichosporon
beigelii
malassezia
furfur
saccharomyc
cerevisia
occasion
hansenula
anomala
risk
hematogen
dissemin
variou
yeast
greater
patient
indwel
vascular
cathet
chemotherapyinduc
mucos
graft
versu
host
diseas
current
cathet
remov
addit
appropri
antifung
therapi
recommend
although
strategi
mean
univers
accept
c
albican
isol
maintain
suscept
fl
uconazol
itraconazol
newer
triazol
agent
voriconazol
also
potent
activ
pathogen
yeast
echinocandin
appear
effect
treatment
candidiasi
caus
candida
speci
treatment
candidiasi
polyen
seldom
necessari
despit
appropri
therapi
overal
mortal
cancer
patient
candidemia
mainli
due
sever
underli
diseas
approach
dissemin
beigelii
infect
respond
less
frequent
dissemin
candidiasi
invas
mold
infect
due
primarili
aspergillu
speci
frequent
caus
seriou
often
lifethreaten
infect
patient
neutropenia
persist
week
risk
factor
includ
impair
cellular
immun
prolong
corticosteroid
administr
allogen
stem
cell
transplant
advanc
age
fumigatu
predomin
speci
isol
nonfumigatu
speci
aspergillu
emerg
signifi
cant
pathogen
common
site
involv
lung
lead
invas
pulmonari
aspergillosi
ipa
common
site
involv
includ
paranas
sinus
central
nervou
system
heart
pericardium
liver
kidney
occasion
bone
joint
cough
dyspnea
hemoptysi
classic
manifest
ipa
may
absent
mute
mani
patient
due
sever
immunosuppress
lead
blunt
infl
ammatori
respons
persist
fever
patient
prolong
neutropenia
despit
appropri
antibiot
therapi
rais
suspicion
invas
fungal
infect
includ
ipa
infect
diagnos
computer
tomographi
ct
imag
classic
fi
nding
includ
nodular
wedgeshap
densiti
halo
sign
cavitari
lesion
fi
nding
chang
evolv
time
respons
therapi
consequ
perform
serial
ct
imag
found
use
monitor
patient
ipa
aspergillu
hypha
angioinvas
natur
result
releas
fungal
antigen
bloodstream
serolog
test
detect
galactomannan
betadglucan
evalu
earli
diagnosi
invas
aspergillosi
former
appear
use
latter
may
also
predictor
outcom
use
test
conjunct
ct
imag
discuss
variou
guidelin
diagnosi
manag
invas
fungal
infect
neutropen
patient
hsct
recipi
sever
moldact
agent
avail
prevent
treatment
invas
aspergillosi
includ
amphotericin
b
lipid
formul
itraconazol
voriconazol
posaconazol
echinocandin
detail
discuss
antifung
prophylaxi
therapi
beyond
scope
chapter
recent
guidelin
address
issu
avail
although
still
uncommon
zygomycosi
mucormycosi
emerg
increasingli
import
infect
past
year
especi
patient
hematolog
malign
hsct
recipi
increas
frequenc
zygomycosi
least
part
attribut
use
voriconazol
variou
indic
antifung
prophylaxi
empir
preemptiv
target
therapi
invas
fungal
infect
common
organ
isol
includ
rhizopu
speci
mucor
speci
cunninghamella
speci
common
site
infect
includ
paranas
sinus
orbit
lung
skin
central
nervou
system
pulmonari
manifest
predomin
neutropen
cancer
patient
gener
dissemin
occur
patient
clinic
featur
often
indistinguish
common
mold
infect
earli
diagnosi
zygomycosi
import
time
therapeut
intervent
ultim
reduc
mortal
improv
surviv
convent
method
laboratori
assess
zygomycosi
includ
direct
examin
cytopatholog
examin
histopatholog
examin
respiratori
relev
specimen
use
immunohistochem
stain
fl
uoresc
situ
hybrid
situ
polymeras
chain
reaction
pcr
may
also
use
cultur
variou
specimen
often
neg
increas
relianc
diagnost
imag
ct
paranas
sinus
chest
may
reveal
earli
fi
nding
even
develop
local
symptom
unlik
invas
aspergillosi
recent
diagnost
therapeut
advanc
improv
overal
surviv
outcom
patient
hematolog
malign
develop
zygomycosi
improv
signifi
cantli
two
system
antifung
reliabl
activ
organ
amphotericin
b
lipid
formul
new
triazol
posaconazol
recent
guidelin
advoc
lipid
prepar
amphotericin
b
fi
rstline
therapi
posaconazol
combin
caspofungin
lipid
prepar
amphotericin
b
secondlin
therapi
surgeri
recommend
rhinocerebr
soft
tissu
infect
revers
underli
risk
factor
import
durat
therapi
remain
unclear
guid
resolut
associ
symptom
fi
nding
mainten
therapi
andor
secondari
prophylaxi
consid
patient
remain
sever
immunosuppress
uncommon
import
mold
caus
invas
infect
patient
hematolog
malign
includ
fusarium
speci
scedosporium
speci
unlik
mold
fungemia
common
patient
fusariosi
may
occur
patient
involv
paranas
sinus
lung
skin
dissemin
infect
also
rel
common
optimum
therapi
remain
defi
ned
overal
outcom
poor
incid
scedosporium
infect
appear
increas
case
prolifi
can
gener
occur
fusariosi
optimum
therapi
remain
defi
ned
overal
prognosi
poor
viral
infect
per
se
uncommon
patient
hematolog
malign
receiv
hsct
hsv
vzv
infect
set
result
reactiv
latent
virus
previou
exposur
primari
infect
rare
us
adult
seroposit
reactiv
occur
patient
undergo
intens
chemotherapi
hematolog
malign
reactiv
usual
occur
soon
chemotherapi
patient
still
sever
neutropen
much
morbid
caus
oral
mucos
attribut
hsv
reactiv
set
consequ
sever
guidelin
recommend
hsv
prophylaxi
patient
undergo
hsct
remiss
induct
therapi
leukemia
reactiv
latent
vzv
also
occur
lesser
extent
risk
consid
insuffi
cient
warrant
routin
prophylaxi
past
two
decad
import
commun
respiratori
virus
signifi
cant
caus
morbid
mortal
hsct
recipi
patient
hematolog
malign
recogn
includ
human
infl
uenza
virus
b
respiratori
syncyti
viru
rsv
human
parainfl
uenza
virus
human
metapneumoviru
human
coronavirus
human
rhinovirus
mani
eg
infl
uenza
virus
rsv
season
preponder
although
encount
year
round
upper
respiratori
tract
infect
urti
predomin
rhinorrhea
common
manifest
progress
lower
respiratori
tract
infect
lrti
lead
respiratori
failur
fatal
outcom
depend
host
factor
intrins
virul
specifi
c
virus
test
respiratori
virus
recommend
highrisk
patient
specimen
diagnost
test
includ
nasopharyng
swab
wash
aspir
tracheal
aspir
bronchoalveolar
lavag
specimen
laboratori
test
includ
nucleic
acid
amplifi
cation
test
direct
antigen
detect
isol
viru
cell
cultur
optimum
therapi
infect
remain
determin
except
human
infl
uenza
virus
pool
publish
studi
variou
center
absenc
suffi
cientli
power
random
control
trial
suggest
treatment
lrti
ribavirin
intraven
immunoglobulin
may
improv
outcom
rsv
infect
approach
also
use
prevent
develop
lrti
hsct
recipi
urti
infect
caus
substanti
amount
morbid
mortal
patient
acut
leukemia
hematolog
malign
neutropenia
predomin
predispos
factor
although
factor
also
contribut
develop
infect
bacteri
infect
predomin
initi
phase
sever
neutropenia
invas
fungal
infect
develop
patient
persist
profound
neutropenia
viral
infect
appear
increas
frequenc
sever
earli
diagnosi
administr
preemptiv
therapi
especi
deal
invas
fungal
infect
import
infect
prevent
develop
resist
limit
avail
therapeut
agent
activ
resist
pathogen
area
global
concern
result
program
antimicrobi
stewardship
infect
control
need
strictli
adher
